Navion Neurosciences is a pre-clinical stage biotechnology company that develops sodium channel therapeutics for neurological diseases.
Navion Neurosciences has raised $10.8M in total funding. The most recent round was Seed. The last funding was announced in September 2026.
Navion Neurosciences's investors include 3B Future Health Fund, Virginia Innovation Partnership Corporation, Angelini Lumira Biosciences Fund, UVA Licensing & Ventures Group, Virginia Tech Carilion (VTC) Innovation Fund.
Navion Neurosciences is headquartered in Charlottesville, United States.
Navion Neurosciences is a pre-clinical stage biotechnology company that develops sodium channel therapeutics for neurological diseases.
Navion Neurosciences is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Navion Neurosciences — Funding & Investors." VCBacked, September 9, 2026, https://www.vcbacked.co/company/genep. Accessed November 13, 2026.
VCBacked. (2026). Navion Neurosciences — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/genep
{{cite web |title=Navion Neurosciences — Funding & Investors |url=https://www.vcbacked.co/company/genep |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Navion Neurosciences? Request a listing update